Kenneth E. Ugen

8.7k total citations · 4 hit papers
121 papers, 6.8k citations indexed

About

Kenneth E. Ugen is a scholar working on Immunology, Virology and Molecular Biology. According to data from OpenAlex, Kenneth E. Ugen has authored 121 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Immunology, 54 papers in Virology and 32 papers in Molecular Biology. Recurrent topics in Kenneth E. Ugen's work include HIV Research and Treatment (54 papers), Immunotherapy and Immune Responses (27 papers) and Immune Cell Function and Interaction (19 papers). Kenneth E. Ugen is often cited by papers focused on HIV Research and Treatment (54 papers), Immunotherapy and Immune Responses (27 papers) and Immune Cell Function and Interaction (19 papers). Kenneth E. Ugen collaborates with scholars based in United States, Mexico and India. Kenneth E. Ugen's co-authors include David B. Weiner, Jean Boyer, Marcia N. Gordon, William V. Williams, Dave Morgan, Donna M. Wilcock, Giovanni DiCarlo, Michael G. Agadjanyan, Kesen Dang and Richard Heller and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Kenneth E. Ugen

120 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

2000 1.2k citations David M. Diamond, Kenneth E. Ugen et al. profile →
Gene inoculation generates immune responses against human immunodeficiency virus type 1.

1993 528 citations Kenneth E. Ugen, Vasantha Srikantan et al. profile →
First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response

1998 503 citations Rob Roy MacGregor, Jean Boyer et al. profile →
Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

2008 503 citations Adil Daud, Ronald C. DeConti et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenneth E. Ugen United States	38	2.6k	2.5k	1.9k	1.5k	992	121	6.8k
Michael G. Agadjanyan United States	37	2.0k 0.8×	1.7k 0.7×	1.5k 0.8×	878 0.6×	762 0.8×	89	4.7k
Kurt Bürki Switzerland	48	6.1k 2.4×	4.4k 1.8×	2.6k 1.4×	424 0.3×	804 0.8×	107	13.8k
Monique F. Stins United States	54	1.8k 0.7×	2.3k 0.9×	666 0.4×	732 0.5×	1.8k 1.8×	89	8.3k
Ulrich Kalinke Germany	58	8.2k 3.2×	3.8k 1.5×	686 0.4×	637 0.4×	1.2k 1.2×	241	14.1k
Michael Bukrinsky United States	51	2.9k 1.1×	4.7k 1.9×	537 0.3×	4.5k 3.0×	673 0.7×	181	10.0k
Rob H. Meloen Netherlands	46	1.7k 0.6×	3.8k 1.6×	132 0.1×	1.2k 0.8×	306 0.3×	166	8.2k
Geneviève Milon France	50	2.8k 1.1×	1.4k 0.6×	552 0.3×	128 0.1×	212 0.2×	144	7.6k
Jonathan Karn United States	62	1.9k 0.7×	8.1k 3.3×	239 0.1×	5.1k 3.4×	324 0.3×	133	12.5k
Wayne I. Lencer United States	62	3.1k 1.2×	5.8k 2.4×	786 0.4×	101 0.1×	604 0.6×	164	11.3k
Gary T. Jennings Switzerland	25	1.6k 0.6×	1.6k 0.6×	374 0.2×	158 0.1×	103 0.1×	36	4.1k

Countries citing papers authored by Kenneth E. Ugen

Since Specialization

Citations

This map shows the geographic impact of Kenneth E. Ugen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth E. Ugen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth E. Ugen more than expected).

Fields of papers citing papers by Kenneth E. Ugen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth E. Ugen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth E. Ugen. The network helps show where Kenneth E. Ugen may publish in the future.

Co-authorship network of co-authors of Kenneth E. Ugen

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth E. Ugen. A scholar is included among the top collaborators of Kenneth E. Ugen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth E. Ugen. Kenneth E. Ugen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chung, Christopher, Kenneth E. Ugen, Niranjan Y. Sardesai, David B. Weiner, & Kar Muthumani. (2016). Protocols for Developing Novel Chikungunya Virus DNA Vaccines. Methods in molecular biology. 1426. 311–332. 3 indexed citations

Sundaram, Senthil G., Colleen Tingey, Nagarajan Muruganandam, et al.. (2013). Nonstructural Protein 2 (nsP2) of Chikungunya Virus (CHIKV) Enhances Protective Immunity Mediated by a CHIKV Envelope Protein Expressing DNA Vaccine. Viral Immunology. 26(1). 75–83. 22 indexed citations

Muthumani, Kar, Mayilvahanan Shanmugam, Andrew Y. Choo, et al.. (2009). Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biology & Therapy. 8(2). 180–187. 13 indexed citations

Daud, Adil, Ronald C. DeConti, Stephanie Andrews, et al.. (2008). Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 26(36). 5896–5903. 503 indexed citations breakdown →

Solórzano-Vargas, R. Sergio, Vitaly Vasilevko, G. Acero, et al.. (2007). Epitope mapping and neuroprotective properties of a human single chain FV antibody that binds an internal epitope of amyloid-beta 1-42. Molecular Immunology. 45(4). 881–886. 20 indexed citations

MacGregor, Rob Roy, Kenneth E. Ugen, Pablo Tebas, et al.. (2005). Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral ?blips?. Vaccine. 23(17-18). 2066–2073. 35 indexed citations

Cao, Chuanhai, et al.. (2004). Characterization of a Novel Human Anti-HIV-1 gp41 IgM Monoclonal Antibody Designated Clone 37. DNA and Cell Biology. 23(12). 836–841. 4 indexed citations

Arendash, Gary W., Marcia N. Gordon, David M. Diamond, et al.. (2003). Short-term β-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP+PS1 mice.. Behavioral Neuroscience. 117(3). 478–484. 35 indexed citations

Román, Raúl Gómez, Chuanhai Cao, Yun Bai, et al.. (2002). Phage-Displayed Mimotopes Recognizing a Biologically Active Anti–HIV-1 gp120 Murine Monoclonal Antibody. JAIDS Journal of Acquired Immune Deficiency Syndromes. 31(2). 147–153. 10 indexed citations

10.

Yang, Joo-Sung, Liesl Nottingham, Kelledy Manson, et al.. (2001). Protection from Immunodeficiency Virus Challenges in Rhesus Macaques by Multicomponent DNA Immunization. Virology. 285(2). 204–217. 32 indexed citations

11.

Cao, Chuanhai, et al.. (2000). High-Level Expression of a Truncated Wall-Associated Protein A from the Dental Cariogenic Streptococcus mutans. DNA and Cell Biology. 19(7). 401–408. 7 indexed citations

12.

Agadjanyan, Michael G., Michael A. Chattergoon, Irina Petrushina, et al.. (1998). Monoclonal Antibodies Define a Cellular Antigen Involved in HTLV-I Infection. Hybridoma. 17(1). 9–19. 5 indexed citations

13.

Mahalingam, Sundarasamy, Brian MacDonald, Kenneth E. Ugen, et al.. (1997). In Vitro and In Vivo Tumor Growth Suppression by HIV-1 Vpr. DNA and Cell Biology. 16(2). 137–143. 36 indexed citations

14.

Ugen, Kenneth E., Srisakul Kliks, Kristina Broliden, et al.. (1996). A Human Monoclonal Antibody to HIV-1 gp41 with Neutralizing Activity Against Diverse Laboratory Isolates. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 12(3). 221–232. 36 indexed citations

15.

Ugen, Kenneth E., et al.. (1994). An Anti-gp41 Human Monoclonal Antibody That Enhances HIV-1 Infection in the Absence of Complement. AIDS Research and Human Retroviruses. 10(1). 13–18. 21 indexed citations

16.

Bhat, Shama, Richard V. Mettus, E. Premkumar Reddy, et al.. (1993). The Galactosyl Ceramide/Sulfatide Receptor Binding Region of HIV-1 gp120 Maps to Amino Acids 206-275. AIDS Research and Human Retroviruses. 9(2). 175–181. 75 indexed citations

17.

Wang, Bin, Michael G. Agadjanyan, Vasantha Srikantan, et al.. (1993). Molecular Cloning, Expression, and Biological Characterization of an HTLV-II Envelope Glycoprotein: HIV-1 Expression Is Permissive for HTLV-II-Induced Cell Fusion. AIDS Research and Human Retroviruses. 9(9). 849–860. 18 indexed citations

18.

Ugen, Kenneth E., James J. Goedert, Jean Boyer, et al.. (1992). Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1.. Journal of Clinical Investigation. 89(6). 1923–1930. 70 indexed citations

19.

McCallus, Daniel E., Kenneth E. Ugen, Alice I. Sato, William V. Williams, & David B. Weiner. (1992). Construction of a Recombinant Bacterial Human CD4 Expression System Producing a Bioactive CD4 Molecule. Viral Immunology. 5(2). 163–172. 42 indexed citations

20.

Osther, Kurt, Allan Wiik, Finn T. Black, et al.. (1992). PASSHIV-1 treatment of patients with HIV-1 infection. A preliminary report of a Phase I trial of hyperimmune porcine immunoglobulin to HIV-1. AIDS. 6(12). 1457–1464. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact